Jones Financial Companies Lllp Acquires 1,182 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Jones Financial Companies Lllp boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 108.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,273 shares of the medical equipment provider’s stock after purchasing an additional 1,182 shares during the quarter. Jones Financial Companies Lllp’s holdings in Lantheus were worth $203,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in LNTH. Geode Capital Management LLC raised its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after acquiring an additional 32,551 shares in the last quarter. Massachusetts Financial Services Co. MA acquired a new position in shares of Lantheus during the 3rd quarter worth $25,955,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock worth $1,041,000 after buying an additional 3,772 shares in the last quarter. Empirical Asset Management LLC acquired a new position in Lantheus in the 4th quarter worth about $323,000. Finally, Focus Financial Network Inc. acquired a new position in Lantheus in the 4th quarter worth about $292,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Performance

NASDAQ:LNTH opened at $99.29 on Friday. The stock has a fifty day moving average of $91.66 and a 200 day moving average of $96.89. Lantheus Holdings, Inc. has a 52-week low of $56.44 and a 52-week high of $126.89. The firm has a market capitalization of $6.80 billion, a price-to-earnings ratio of 16.52 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. Equities analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on LNTH. The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target on the stock. Truist Financial upped their price target on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. Finally, StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $132.86.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.